INR 906.95
(1.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 61.27 Billion INR | 6.29% |
2022 | 57.64 Billion INR | 23.33% |
2021 | 46.74 Billion INR | 11.92% |
2020 | 41.76 Billion INR | -39.63% |
2019 | 69.17 Billion INR | 3.88% |
2018 | 66.59 Billion INR | 19.29% |
2017 | 55.82 Billion INR | -1.09% |
2016 | 56.43 Billion INR | -6.52% |
2015 | 60.37 Billion INR | -2.29% |
2014 | 61.78 Billion INR | 1.69% |
2013 | 60.76 Billion INR | 4.29% |
2012 | 58.26 Billion INR | 6.96% |
2011 | 54.47 Billion INR | 1.82% |
2010 | 53.49 Billion INR | 16.67% |
2009 | 45.85 Billion INR | -14.07% |
2008 | 53.36 Billion INR | 80.69% |
2007 | 29.53 Billion INR | 26.36% |
2006 | 23.37 Billion INR | 93.04% |
2005 | 12.1 Billion INR | 59.66% |
2004 | 7.58 Billion INR | 14.92% |
2003 | 6.59 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 59.97 Billion INR | 210.63% |
2024 Q1 | -54.21 Billion INR | -188.47% |
2023 Q3 | - INR | -100.0% |
2023 Q1 | - INR | -100.0% |
2023 FY | 61.27 Billion INR | 6.29% |
2023 Q2 | 59.98 Billion INR | 0.0% |
2023 Q4 | 61.27 Billion INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 52.33 Billion INR | 0.0% |
2022 FY | 57.64 Billion INR | 23.33% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 57.64 Billion INR | 0.0% |
2021 Q4 | 46.74 Billion INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 Q1 | - INR | -100.0% |
2021 Q2 | 43.73 Billion INR | 0.0% |
2021 FY | 46.74 Billion INR | 11.92% |
2020 FY | 41.76 Billion INR | -39.63% |
2020 Q1 | - INR | -100.0% |
2020 Q2 | 64.07 Billion INR | 0.0% |
2020 Q3 | - INR | -100.0% |
2020 Q4 | 41.76 Billion INR | 0.0% |
2019 FY | 69.17 Billion INR | 3.88% |
2019 Q1 | - INR | -100.0% |
2019 Q3 | - INR | -100.0% |
2019 Q4 | 69.17 Billion INR | 0.0% |
2019 Q2 | 66.62 Billion INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 FY | 66.59 Billion INR | 19.29% |
2018 Q4 | 66.59 Billion INR | 0.0% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 61.22 Billion INR | 0.0% |
2017 Q2 | 56.72 Billion INR | 0.0% |
2017 Q1 | - INR | -100.0% |
2017 Q3 | - INR | -100.0% |
2017 Q4 | 55.82 Billion INR | 0.0% |
2017 FY | 55.82 Billion INR | -1.09% |
2016 Q2 | 54.94 Billion INR | 0.0% |
2016 Q4 | 56.43 Billion INR | 0.0% |
2016 FY | 56.43 Billion INR | -6.52% |
2016 Q1 | - INR | -100.0% |
2016 Q3 | - INR | -100.0% |
2015 Q2 | 61.15 Billion INR | 0.0% |
2015 Q4 | 60.37 Billion INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2015 FY | 60.37 Billion INR | -2.29% |
2015 Q3 | - INR | -100.0% |
2014 Q2 | 61.81 Billion INR | 0.0% |
2014 Q1 | - INR | -100.0% |
2014 Q4 | 61.78 Billion INR | 0.0% |
2014 Q3 | - INR | -100.0% |
2014 FY | 61.78 Billion INR | 1.69% |
2013 FY | 60.76 Billion INR | 4.29% |
2013 Q2 | 62.08 Billion INR | 0.0% |
2013 Q3 | - INR | -100.0% |
2013 Q1 | - INR | -100.0% |
2013 Q4 | 60.76 Billion INR | 0.0% |
2012 Q4 | 58.26 Billion INR | 0.0% |
2012 FY | 58.26 Billion INR | 6.96% |
2012 Q3 | - INR | 0.0% |
2011 FY | 54.47 Billion INR | 1.82% |
2011 Q4 | 54.47 Billion INR | 0.0% |
2010 FY | 53.49 Billion INR | 16.67% |
2009 FY | 45.85 Billion INR | -14.07% |
2008 FY | 53.36 Billion INR | 80.69% |
2007 FY | 29.53 Billion INR | 26.36% |
2006 FY | 23.37 Billion INR | 93.04% |
2005 FY | 12.1 Billion INR | 59.66% |
2004 FY | 7.58 Billion INR | 14.92% |
2003 FY | 6.59 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Amrutanjan Health Care Limited | 783.82 Million INR | -7717.316% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -21116.832% |
Caplin Point Laboratories Limited | 3.5 Billion INR | -1647.889% |
FDC Limited | 3.7 Billion INR | -1551.943% |
Gufic Biosciences Limited | 5.59 Billion INR | -994.216% |
Hikal Limited | 12.99 Billion INR | -371.523% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | -2576.35% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -868.162% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -9416.325% |
Medico Remedies Limited | 438.24 Million INR | -13881.709% |
Nectar Lifesciences Limited | 11.21 Billion INR | -446.207% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -38246.34% |
RPG Life Sciences Limited | 1.38 Billion INR | -4339.502% |
Sequent Scientific Limited | 8.27 Billion INR | -640.538% |
Shilpa Medicare Limited | 12.93 Billion INR | -373.799% |
Sigachi Industries Limited | 2.53 Billion INR | -2320.687% |
Themis Medicare Limited | 1.88 Billion INR | -3146.286% |
Unichem Laboratories Limited | 8.06 Billion INR | -659.352% |
Venus Remedies Limited | 1.39 Billion INR | -4299.339% |
Wanbury Limited | 3.15 Billion INR | -1841.805% |
ZIM Laboratories Limited | 2.08 Billion INR | -2844.787% |
Lupin Limited | 96.23 Billion INR | 36.33% |
Innova Captab Limited | 4.89 Billion INR | -1150.523% |
Ind-Swift Limited | 13.45 Billion INR | -355.468% |
Bajaj HealthCare Limited | 4.86 Billion INR | -1158.796% |
Aurobindo Pharma Limited | 152.2 Billion INR | 59.743% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | -334.82% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | -1573.646% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | -3000.423% |
Morepen Laboratories Limited | 4.45 Billion INR | -1273.922% |
Laurus Labs Limited | 42.71 Billion INR | -43.45% |
Aarti Drugs Limited | 11.5 Billion INR | -432.632% |
Glenmark Life Sciences Limited | 5.18 Billion INR | -1082.69% |
Alembic Limited | 1.43 Billion INR | -4178.612% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | -276.519% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 5.893% |
Vaishali Pharma Limited | 371.16 Million INR | -16408.65% |
Aarti Pharmalabs Limited | 8.25 Billion INR | -642.652% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -20547.661% |
Eris Lifesciences Limited | 38.26 Billion INR | -60.118% |
Windlas Biotech Limited | 1.76 Billion INR | -3376.145% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 66.621% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -5602.321% |
Orchid Pharma Limited | 3.84 Billion INR | -1493.984% |
Albert David Limited | 1.15 Billion INR | -5227.687% |
Hester Biosciences Limited | 3.59 Billion INR | -1604.556% |
Sakar Healthcare Limited | 1.26 Billion INR | -4750.389% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | -2912.149% |
Procter & Gamble Health Limited | 2.56 Billion INR | -2292.394% |
Divi's Laboratories Limited | 18.99 Billion INR | -222.665% |
Mankind Pharma Limited | 23.87 Billion INR | -156.649% |
Neuland Laboratories Limited | 5.49 Billion INR | -1014.364% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -472.226% |
Zydus Lifesciences Limited | 71.79 Billion INR | 14.651% |
Wockhardt Limited | 39.87 Billion INR | -53.684% |
Bal Pharma Limited | 2.51 Billion INR | -2339.955% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 42.717% |
Bliss GVS Pharma Limited | 2.1 Billion INR | -2805.563% |
Alkem Laboratories Limited | 48.6 Billion INR | -26.065% |
Valiant Laboratories Limited | 1.05 Billion INR | -5690.065% |
Ajanta Pharma Limited | 10.71 Billion INR | -472.103% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -9293.833% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -3457.917% |
Granules India Limited | 22.95 Billion INR | -166.938% |
Medicamen Biotech Limited | 940.36 Million INR | -6415.967% |
Ipca Laboratories Limited | 33.74 Billion INR | -81.591% |
Brooks Laboratories Limited | 248.6 Million INR | -24547.528% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -5158.618% |
Piramal Enterprises Limited | 560.47 Billion INR | 89.068% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 25.321% |
NATCO Pharma Limited | 10.53 Billion INR | -481.789% |
Suven Life Sciences Limited | 148.62 Million INR | -41128.359% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1960.382% |
Strides Pharma Science Limited | 37.68 Billion INR | -62.615% |
Indoco Remedies Limited | 10.34 Billion INR | -492.46% |
Alpa Laboratories Limited | 307.12 Million INR | -19851.029% |
Lasa Supergenerics Limited | 541.92 Million INR | -11206.731% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -1473.994% |